Patent intelligence · US
US 11045425
Method of encapsulating pancreatic islet cells introduced to siRNA against PHLDA3
Method of encapsulating pancreatic islet cells introduced to siRNA against PHLDA3
Patent details — US 11045425
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 29, 2021
- Expiration
- Jun 24, 2041
- Applicant
- KURARAY CO., LTD.
- Claims
- 5
- CPC classes
- A61K, A61K2121/00, A61K31/7088, A61K31/7105
Quick answer
US 11045425 (Method of encapsulating pancreatic islet cells introduced to siRNA against PHLDA3) is held by KURARAY CO., LTD.. Status: granted. Granted Jun 29, 2021. Expires Jun 24, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- KURARAY CO., LTD.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K2121/00, A61K31/7088, A61K31/7105, A61K35/39, A61K45/00
More from KURARAY CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12410184
Crystalline forms of a menin inhibitor
granted -
US 12377026
Dental adhesive material kit
granted -
US 12358210
Resin composition for stereolithography
granted -
US 12344691
Resin composition for stereolithography
granted -
US 12214061
Adhesive composition for dental use
granted -
US 12208148
Dental restorative curable composition
granted -
US 12145888
Zirconia molded body and pre-sintered body capable of being sintered in short time
granted -
US 12138325
Dental composition
granted
Frequently asked questions
What is US patent 11045425?
US 11045425 (Method of encapsulating pancreatic islet cells introduced to siRNA against PHLDA3) is held by KURARAY CO., LTD.. Status: granted. Granted Jun 29, 2021. Expires Jun 24, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11045425?
KURARAY CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 132 pharmaceutical patents for this assignee.
When does US 11045425 expire?
Our index shows an expiration date of Jun 24, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.